A citation-based method for searching scientific literature

Lian A van Meijel, Hanne M Rooijackers, Cees J Tack, Bastiaan E de Galan. J Clin Endocrinol Metab 2019
Times Cited: 4







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
50

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
50

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
51
50

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
50

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Tina Vilsbøll, Henrik Ullits Andersen, Filip Krag Knop. BMJ Open 2018
2
100

The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
L-L Jiang, S-Q Wang, B Ding, J Zhu, T Jing, L Ye, K-O Lee, J-D Wu, J-H Ma. J Endocrinol Invest 2018
5
50



Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
50

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
50

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
597
50

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
25

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
939
25

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
25

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Juris J Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A Menge, Thomas Forst, Christoph Kapitza. Diabetes Care 2015
160
25

Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries.
Ruth S Weinstock, Ingrid Schütz-Fuhrmann, Crystal G Connor, Julia M Hermann, David M Maahs, Morten Schütt, Shivani Agarwal, Sabine E Hofer, Roy W Beck, Reinhard W Holl. Diabetes Res Clin Pract 2016
25
25

Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
Khalid Al Ghofaili, Michelle Fung, Ziliang Ao, Mark Meloche, R Jean Shapiro, Garth L Warnock, Dariush Elahi, Graydon S Meneilly, David M Thompson. Transplantation 2007
96
25




Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
736
25



Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
25


Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
121
25

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
25

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
25

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50
25

GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas. Hellenic J Cardiol 2019
16
25


Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
Thomas A Pearson, George A Mensah, R Wayne Alexander, Jeffrey L Anderson, Richard O Cannon, Michael Criqui, Yazid Y Fadl, Stephen P Fortmann, Yuling Hong, Gary L Myers,[...]. Circulation 2003
25

Oxidatively generated modifications to nucleic acids in vivo: Measurement in urine and plasma.
Henrik E Poulsen, Allan Weimann, Trine Henriksen, Laura Kofoed Kjær, Emil List Larsen, Elin Rebecka Carlsson, Cramer K Christensen, Ivan Brandslund, Mogens Fenger. Free Radic Biol Med 2019
15
25

Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation.
Gemma Llauradó, Victòria Ceperuelo-Mallafré, Carme Vilardell, Rafael Simó, Núria Freixenet, Joan Vendrell, José Miguel González-Clemente. Diabetes Care 2012
51
25

Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study.
Ewa Konduracka, Grazyna Cieslik, Danuta Galicka-Latala, Pawel Rostoff, Artur Pietrucha, Pawel Latacz, Grzegorz Gajos, Maciej T Malecki, Jadwiga Nessler. Acta Diabetol 2013
24
25

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad,[...]. Lancet Diabetes Endocrinol 2020
11
25

Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.
Shona J Livingstone, Daniel Levin, Helen C Looker, Robert S Lindsay, Sarah H Wild, Nicola Joss, Graham Leese, Peter Leslie, Rory J McCrimmon, Wendy Metcalfe,[...]. JAMA 2015
255
25

Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
Antonio Ceriello, Anna Novials, Emilio Ortega, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Dario Giugliano, Stefano Genovese. Diabetes Care 2013
107
25

Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine.
Dorte Vistisen, Gregers Stig Andersen, Christian Stevns Hansen, Adam Hulman, Jan Erik Henriksen, Henning Bech-Nielsen, Marit Eika Jørgensen. Circulation 2016
63
25

Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial.
Sanne Tofte Rasmussen, Jon Trærup Andersen, Torben Kjær Nielsen, Vanja Cejvanovic, Kasper Meidahl Petersen, Trine Henriksen, Allan Weimann, Jens Lykkesfeldt, Henrik Enghusen Poulsen. Redox Biol 2016
46
25


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
25

Association between CD4+, CD25+, FOXP3+ Regulatory T-cells and Cardiovascular Complications in Diabetic Patients Type 1.
Reham M El-Shabrawy, Azza M Ahmed, Fayrouz O Selim, Nora M Said. Egypt J Immunol 2019
3
33

Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
Tam Nguyen Dinh, Tin Soe Kyaw, Peter Kanellakis, Kelly To, Peter Tipping, Ban-Hock Toh, Alexander Bobik, Alex Agrotis. Circulation 2012
110
25

Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Marie-Christine Dubé, Martin D'Amours, S John Weisnagel. Diabetes Obes Metab 2018
13
25

Temporal patterns in overweight and obesity in Type 1 diabetes.
B Conway, R G Miller, T Costacou, L Fried, S Kelsey, R W Evans, T J Orchard. Diabet Med 2010
179
25

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet Med 2015
178
25

N-terminal pro brain natriuretic peptide reflects long-term complications in type 1 diabetes.
Jakob Grauslund, Mads Nybo, Anders Green, Anne K Sjølie. Scand J Clin Lab Invest 2010
11
25

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
46
25

Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study.
Laura K Kjær, Vanja Cejvanovic, Trine Henriksen, Kasper M Petersen, Torben Hansen, Oluf Pedersen, Cramer K Christensen, Christian Torp-Pedersen, Thomas A Gerds, Ivan Brandslund,[...]. Diabetes Care 2017
30
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.